Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS0728 in advanced solid tumors with HER2/HER3 abnormalities
NCT03410927Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Apr 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of TAS0728 in solid tumor (advanced stage), urothelial carcinoma (UC), biliary tract cancer (BTC) and 5 more, sponsored by Taiho Oncology. Primary endpoints: Dose Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events and 1 more. Started Apr 2018; status: terminated.
02
Drugs
TAS0728
03
Conditions
solid tumor (advanced stage)urothelial carcinoma (UC)biliary tract cancer (BTC)breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03410927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03410927.